IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Socinski, Mark A.; Nishio, Makoto; Jotte, Robert M.; Cappuzzo, Federico; Orlandi, F; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A.; Barlési, Fabrice; Finley, Gene Grant; Kong, Shengchun; Lee, Anthony; Coleman, Shelley; Zou, Wei; McCleland, Mark L.; Shankar, Geetha; Reck, Martin

doi:10.1016/j.jtho.2021.07.009

Cited by 280 publications

(224 citation statements)

References 27 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…However, in the final analyses of IMPower150, the additional effect of atezolizumab resulted in a numeric, but not statistically significant, improvement in OS. This may be correlated with PD-L1 expression on tumor cells [50].…”

Section: Atezolizumabmentioning

confidence: 92%

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

Kinoshita

Terai

Yaguchi

2021

Life

View full text Add to dashboard Cite

The three major conventional treatments: surgery, chemotherapy, and radiation therapy, have been commonly performed for lung cancer. However, lung cancer is still the leading cause of cancer-related mortality. Immunotherapy has recently emerged as a very effective new treatment modality, and there is now growing enthusiasm for cancer immunotherapy worldwide. However, the results of clinical studies using immunotherapy are not always favorable. Understanding the steps involved in the recognition and eradication of cancer cells by the immune system seems essential to understanding why past immunotherapies have failed and how current therapies can be optimally utilized. In addition, the combination of immunotherapies, such as cancer vaccines and immune checkpoint inhibitors, as well as the combination of these therapies with three conventional therapies, may pave the way for personalized immunotherapy. In this review, we summarize the results of immunotherapies used in phase III clinical trials, including immune checkpoint inhibitors, and discuss the future prospects of immunotherapies in lung cancer treatment.

show abstract

Section: Atezolizumabmentioning

confidence: 92%

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

Kinoshita

Terai

Yaguchi

2021

Life

View full text Add to dashboard Cite

show abstract

“… 343 , 344 Later, in 2018, based on the IMpower150 trial (NCT02366143), atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin was approved for the first‐line treatment of advanced nonsquamous NSCLC without EGFR or ALK mutation. 345 In 2020, the U.S. FDA expanded the indication of atezolizumab to first‐line treatment of advanced NSCLC with PD‐L1 expression ≥ 50% as a single agent. The efficacy was evaluated in the IMpower110 trial with median OS of 20.2 months compared to 13.1 months in chemotherapy arm.…”

Section: Immunotherapy For Nsclcmentioning

confidence: 99%

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Yuan

Zhang

2021

MedComm

View full text Add to dashboard Cite

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past decades, despite the rapid development of targeted therapy and immunotherapy in non‐small cell lung cancer (NSCLC). The development and availability of comprehensive genomic profiling make the classification of NSCLC more precise and personalized. Most treatment decisions of advanced‐stage NSCLC have been made based on the genetic features and PD‐L1 expression of patients. For the past 2 years, more than 10 therapeutic strategies have been approved as first‐line treatment for certain subgroups of NSCLC. However, some major challenges remain, including drug resistance and low rate of overall survival. Therefore, we discuss and review the therapeutic strategies of NSCLC, and focus on the development of targeted therapy and immunotherapy in advanced‐stage NSCLC. Based on the latest guidelines, we provide an updated summary on the standard treatment for NSCLC. At last, we discussed several potential therapies for NSCLC. The development of new drugs and combination therapies both provide promising therapeutic effects on NSCLC.

show abstract

“…On the basis of the potential immunogenic properties of anti-vascular endothelial growth factor (VEGF) inhibitors, IMpower150 investigated the role of the atezolizumab-chemotherapy combination, and the potential added benefits of bevacizumab, in the first-line setting in 1202 patients with non-squamous NSCLC and any level of PD-L1 expression [ 21 , 22 ]. EGFR mutations and ALK translocations were allowed if there had been progression or intolerance to a TKI.…”

Section: Immunotherapy With Chemotherapymentioning

confidence: 99%

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

Denault

Melosky²

2021

Current Oncology

View full text Add to dashboard Cite

Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following four sections: single-agent immunotherapy, immunotherapy and chemotherapy, dual immunotherapy, and dual immunotherapy and chemotherapy. The results are summarized and tabulated. Finally, application of the trial data is illustrated in four clinical scenarios depending on the programmed death-ligand 1 (PD-L1) expression levels. Single checkpoint inhibitors have become an easy and excellent treatment in patients whose tumors have high PD-L1 expression. Adding chemotherapy to immunotherapy benefits our patients. Immunotherapy, with or without chemotherapy, is now the standard of care in the first-line setting in patients without EGFR, ALK, or ROS driver mutations.

show abstract

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Cited by 280 publications

References 27 publications

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Immunotherapy in the First-Line Setting in Wild-Type NSCLC

Contact Info

Product

Resources

About